At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Maintenance Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Ovarian Cancer and 2 related conditions. Completed, enrolled 20 participants across 4 sites.
Detailed Summary
The overall aim of the study is to demonstrate a clinically meaningful extension of progression free survival using maintenance pembrolizumab. The aim of the translational research is to study the immune microenvironment before and during pembrolizumab therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
CountriesUnited Kingdom
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMay 2019
Primary CompletionDec 2025
TodayJul 2026
First PostedFeb 13, 2018
Enrollment StartMay 16, 2019
Primary CompletionDec 3, 2025
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 8.4 years ago
Interventions
Pembrolizumabdrug
Intravenous infusion